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ABSTRACT
Immunoaffinity Monoliths for Multiplexed Extraction of Preterm Birth Biomarkers from Human
Blood Serum in 3D Printed Microfluidic Devices
Haifa Mohammad Almughamsi
Department of Chemistry and Biochemistry, BYU
Doctor of Philosophy
Preterm birth (PTB) results in over 15 million early births annually and is the leading
cause of neonatal deaths. There are no clinical methods currently available to evaluate risk of
PTB at early stages in pregnancy; thus, a rapid diagnostic to analyze PTB risk would be
beneficial. Microfluidic immunoaffinity extraction is a promising platform for preparing
complex samples, such as maternal serum with PTB risk biomarkers. 3D printed microfluidic
devices have advantages over conventional microfluidic systems including simple fabrication
and potential for iterative optimization to improve designs. In this work, I developed
immunoaffinity monoliths in 3D printed microfluidic devices modified with antibodies to enrich
PTB biomarkers from human blood serum. I retained and eluted a peptide PTB biomarker in
both buffer and blood serum using an immunoaffinity column. An additional three PTB
biomarkers were also successfully extracted either from buffer or blood serum on singleantibody columns. Both polyclonal and monoclonal antibodies to PTB biomarkers were
characterized by dot blots, biolayer interferometry, and surface plasmon resonance to determine
their specificity and dissociation constants. I created multiplexed immunoaffinity columns to
simultaneously enrich three PTB biomarkers from depleted human blood serum in a single
extraction. This is the first demonstration of multiplexed immunoaffinity columns for PTB
biomarkers in a 3D printed microfluidic device. My work is a key step towards the future
development of 3D printed microfluidic devices for rapid PTB testing.

Keywords: preterm birth (PTB), laser induced fluorescence (LIF), porous polymer monolith,
multiplexed antibodies, immunoaffinity extraction, 3D printing, point of care (POC)
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1. INTRODUCTION
1.1 Preterm Birth
Preterm birth (PTB) is birth prior to 37 weeks of pregnancy. It is the most common type
of pregnancy complication with an incidence rate of 1 out of every 9 births in the United
States.1-4 PTB is also a contributing cause in most neonatal deaths. PTB infants can have
multiple problems through their lives including hearing and vision loss, acute respiratory failure,
behavioral problems, sensory difficulty, and chronic lung disease.5 A variety of causes have been
investigated, but in the majority of PTB cases no specific cause is found. Thus, there is a major
need for an inexpensive and rapid diagnostic method that can accurately evaluate the risk of PTB
at an early stage of pregnancy.
Nine PTB biomarkers were identified that show significant predictive power for the onset
of early labor as seen in Table 1.1.1 These biomarkers found in maternal blood serum include
four previously known proteins: ferritin, lactoferrin, thrombin-antithrombin complex, and tumor
necrosis factor-receptor type 1; and two peptides: corticotropin-releasing factor and defensin.
Furthermore, Esplin and collaborators1 have discovered three additional serum peptide
biomarkers. Peptides 1-3 are fragments of a larger protein called inter-alpha-trypsin inhibitor
heavy chain 4 (ITIH4). This panel of nine maternal serum biomarkers allows for PTB prediction
with 90% selectivity and 80% specificity.
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Table 1.1 PTB biomarkers.

*Level is not known

1.2 Biomarker Analysis
Several approaches are available for clinical biomarker analysis including liquid
chromatography,6 enzyme-linked immunosorbent assay (ELISA),7 and mass spectrometry.6
These bioanalytical methods can achieve reliable results, but are expensive, time-consuming, and
not portable. Additionally, these approaches require many sample preparation steps and an
experienced technician to generate accurate results.
Liquid chromatography coupled with mass spectrometry (LC-MS) offers selective and
sensitive analysis for a variety of biomarkers.6 However, the sample preparation steps prior to
LC-MS limit the success of this technique for analysis of multiple biomarkers.8 Esplin and
collaborators1 purified PTB peptides from serum proteins using sample precipitation to access
the low molecular weight proteome prior to LC-MS analysis. All these intensive steps hinder
biomarker quantification.
ELISA is a robust technique that is widely used in clinical biomarker analysis, though
challenges exist for multiplexing.7 Sandwich immunoassay can measure proteins due to the
multiple epitopes available, but peptides must be detected by competitive immunoassay due to
2

their small size.9 Both these assays are still limited by difficulties in multiplexing and lower
sensitivity and specificity for competitive immunoassay. Both LC-MS and ELISA are not ideal
options to analyze this combined panel of serum proteins and peptides related to PTB. Thus, an
improved analysis method for PTB biomarkers is needed.
1.3 Microfluidics
Microfluidics involves controlling and manipulating liquids at the sub microliter scale.10
The small volumes of liquid are passed through tiny channels in a device often called a lab-on-achip11 where they can react, be analyzed, or manipulated.
Due to their micro-scale dimensions (<100 µm), microfluidic devices offer multiple
advantages over conventional laboratory techniques. Microfluidic devices use lower volumes of
sample and reagents, making this technology ideal for handling costly or toxic reagents.12
Moreover, the small size of microfluidic devices results in faster analysis times, better
temperature control, lower energy consumption, and portability.11 All these benefits make
microfluidic devices a promising platform for sensitive and cheap analysis of PTB biomarkers.
Originally, microfluidic devices were fabricated in silicon or glass using
photolithography. This fabrication technique requires multiple processes, such as patterning,
bonding, and etching steps.13,14 All these processes are costly and complicate device fabrication,
so alternative techniques to overcome these limitations are needed.15
1.4 3D Printing
Three-dimensional (3D) printing is an additive manufacturing process that creates 3D
objects layer by layer using a computer designed file.16 3D printing has numerous advantages
over traditional microfabrication including lower costs, fewer toxic chemicals, and increased
portability because it does not require use of a cleanroom environment.17,18 These features make
3

3D printing useful in many applications like dentistry and the aerospace industry to create
precise models, prototypes, and patterns.19 Recently, 3D printed microdevices have received
attention due to the wide variety of benefits this technique offers such as rapid, iterative
optimization where experimental data can provide feedback to improve design.20
Stereolithography (SLA) is one type of 3D printing which uses a liquid resin that is
photopolymerized one layer at a time by exposure to UV light. A customized SLA 3D printer
built by Nordin’s group20 at BYU has been used to make 20 μm × 20 μm channels in complex
fluidic patterns, and Gong et al.21,22 showed that pumps and valves can be 3D printed for
microfluidic channels providing a pressure driven system.
Microfluidic channels can also be 3D printed and used for PTB biomarker analysis.23
Parker et al.24 developed an immunoaffinity monolith in 45 μm × 50 μm cross section
microfluidic channels in a 3D printed microfluidic device to purify ferritin from human blood
serum. Bickham et al.25 adapted this design to polymerize a solid-phase extraction monolith to
retain and elute this panel of nine PTB biomarkers. Creating microfluidic channels in a 3D
printed device is possible, and when coupled with monolithic columns, will significantly advance
the field of biomarker isolation and identification.
1.5 Monoliths
A monolith is a porous polymer, which has been researched for more than two decades
resulting in the development of many applications.26 Monolithic columns are used in
chromatography applications and fabricated from multiple materials such as silica or polymers.27
Monoliths allow in situ polymerization24- 25,28 and can be formulated to have a high flow rate,
reduced mass transfer resistance, and low backpressure compared to traditional packed bead
columns.27 Affinity monoliths can be created by using different microfluidic channel materials to
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retain analytes on the antibody column.24,29
An immunoaffinity monolith uses reactive monomer, glycidylmethacrylate (GMA), a
cross linker like ethylene dimethacrylate (EDMA), porogens like cyclohexanol and dodecanol,
and a photoinitatior.24,29 These components are well researched, commercially available, and
easy to prepare. The monomer and cross linker determine the properties of the monolith, such as
the polarity, and polymerized structure. The crosslinker also determines the rigidity and pore size
of the monolith. The porosity and surface area of the monolith can be controlled by adjusting the
ratio of the porogens in the monolith formulation.
The GMA monolith surface can be functionalized to immobilize the target. For instance,
antibodies can be covalently immobilized to a GMA column in one step by an epoxy group24 or
in multiple steps by the Schiff base method.30 After antibody binding, the biomolecule of interest
passes through the column and binds specifically to its target. Then, rinsing buffer is applied to
remove weakly bound or non-retained analytes. Next, the elution buffer is flowed through the
column and the biomolecule dissociates from its target. Immunoaffinity monoliths methods are
widely used to retain analytes in a column via immobilized antibodies.
Several other methods and applications of affinity monoliths are also reported. Knob et
al.31 developed affinity monoliths modified with oligonucleotides and polymerized in a
microfluidic device to capture DNA for sepsis diagnosis. Monoliths can be easily created inside
a microchannel, offering a useful support for many applications.
1.6 Immunoassays
An immunoassay is a biochemical technique commonly used in biomarker analysis14 to
detect a target analyte in a mixture through a high affinity antibody. It works by binding of an
antibody to a solid surface, which an antigen is then flowed over. This allows for the formation
5

of antibody-antigen complex. The ability of the antibody to recognize a specific antigen is
necessary as it allows analysis of a range of analytes. The work described in this dissertation
focuses on measuring multiple PTB biomarkers after they bind to their target antibodies on an
affinity monolith. The enrichment of these biomarkers will make use of immunoaffinity
monoliths in a simple 3D printed microfluidic chip possible.
1.6.1 Immunoassays in Microfluidics
Immunoassays in microfluidics are advantageous due to the low volume required, the
ease of use, and potential for automation.12 Developing an immunoassay in a microfluidic device
further has the ability to provide a point of care analysis platform.
1.6.2 Antibodies
Antibodies are glycoproteins that have high selectivity and specificity toward their
binding target. Antibodies are widely used in microfluidic immunoassays.24,32 They have the
capability to be immobilized on several support types. For instance, antibodies can be
immobilized in a porous monolith inside a microfluidic channel, or on beads, or
nanoparticles.24,29, 33-34
Antibodies are composed of four polypeptide chains (two heavy and two light
polypeptide chains) and form a “Y” shape as seen in Figure 1.1. The polypeptide chains are
connected to each other by disulfide bonds. Each arm of “Y” called the Fab region, contains an
antigen binding site that recognizes an epitope on a specific antigen. This region contains one
constant and one variable domain from each (heavy and light) chain of the antibody. The base of
the “Y” is called the Fc region and contains two heavy chains. Polyclonal and monoclonal
antibodies are the main antibody types used in immunoassay.

6

Figure 1.1: Diagram of an antibody.

1.6.2.1 Monoclonal and Polyclonal Antibodies
Antibodies used in immunoassay are monoclonal and polyclonal, and each type has its
own pros and cons. Monoclonal antibodies are homogenous. They are produced from a single B
cell; therefore, they recognize only one specific epitope of the antigen. Monoclonal antibodies
have low cross reactivity with other proteins but are expensive to produce.35
Polyclonal antibodies are heterogeneous. They are made from multiple B cells and are easier to
produce than monoclonal antibodies. Polyclonal antibodies are able to recognize different
epitope sites in the same antigen.35 Because polyclonal antibodies recognize many different
epitopes on a single antigen, cross reactivity is more common in this antibody type.36 Polyclonal
antibody specificity is also reduced compared to a monoclonal antibody.
1.6.2.2 Dot Blot
A dot blot is a simple, yet powerful molecular biology technique, performed to determine
an antibody’s compatibility toward specific antigens. The dot blot process is a straightforward
method where the antigens of interest are dotted on a nitrocellulose membrane. Then, the
membrane is blocked to prevent non-specific binding. After blocking, the membrane is rinsed
7

and the target antibody is incubated to bind to its antigen. Next, a secondary antibody is
incubated for fluorescence detection. Last, the membrane is scanned to determine whether the
antigen and antibody are compatible, indicated by presence of fluorescence dots.

Figure 1.2 Dot blot process. A) Nitrocellulose membrane. B) PTB biomarker dots. C) Blocking agent
applied (blue). D) Primary antibody added (red). E) Secondary antibody applied (dark green). E) Dot blot
image after scanning.

1.7 Biolayer Interferometry and Surface Plasmon Resonance
Biolayer interferometry (BLI) and surface plasmon resonance (SPR) are widely used
optical biosensing techniques that measure biomolecular interactions.37-39 BLI analyzes the
interference patterns of white light reflected from two surfaces. The first surface has immobilized
proteins on the biosensor tip, whereas the second surface is an internal reference layer from the
instrument. Binding between the analyte in the solution and the ligand immobilized on the
biosensor tip causes an increase in the optical thickness, which leads to a wavelength shift and
thus a change in the interference which is measured in real time. In SPR, one binding partner is
attached to the surface of the sensor tip while the other partner is injected in continuous flow.40
SPR measures changes in the intensity of light reflected at a specific angle from the glass side of
the sensor surface. When a molecule binds to the sensor surface, the refractive index near the
surface changes, which alters the angle of minimum reflected intensity. The change in SPR angle
8

is proportional to the mass of material bound. Both BLI and SPR assays have the ability to
measure binding specificity and rate of association and dissociation with high precision and
accuracy.40
1.7.1 Dissociation Constant (Kd)
Binding affinity between a biomolecule and its target can be assessed by the
equilibrium dissociation constant (Kd). High binding affinity between an antigen and its target is
indicated by a lower Kd value, while a higher Kd value shows lower binding affinity between
antigen and target. Understanding the kinetics of the interaction between each biomarker and its
target antibody can help to distinguish between retention of different biomarkers when multiple
antibodies are attached to an immunoaffinity column.

1.8 Dissertation Overview
In this dissertation, I describe the development of 3D printed microfluidic devices for
early detection of PTB risk. The devices contain an affinity monolith that is antibody modified,
which will allow me to extract PTB biomarkers. This work shows the ability to purify multiple
PTB biomarkers from human blood serum in 3D printed microfluidic devices.
Chapter 2 describes the development of immunoaffinity monoliths to extract the PTB
peptide biomarker corticotropin releasing factor (CRF) from human blood serum in a 3D printed
microfluidic device. Successful retention and elution of CRF is achieved in both buffer and
blood serum from the anti-CRF column. This work is the first demonstration of PTB peptide
extraction by an immunoaffinity column in a 3D-printed device. This is a significant step
towards the analysis of a panel of PTB biomarkers in human blood serum as part of a PTB risk
diagnostic.

9

Chapter 3 demonstrates the characterization of antibodies targeting PTB biomarkers.
Selective binding between PTB biomarkers and off-target antibodies is demonstrated.
Immunoaffinity extraction of the following individual PTB biomarkers, ferritin, lactoferrin and
peptide 2, in 3D printed microfluidic devices is reported. This chapter also describes the binding
affinity, or dissociation constant, for PTB biomarkers toward their targeted antibodies. The
dissociation constants reported in this chapter are for polyclonal antibodies toward several of the
PTB biomarkers. This work provides a promising foundation for extraction of multiple PTB
biomarkers on immunoaffinity columns.
Chapter 4 shows the successful development of multiplexed immunoaffinity monoliths
for extraction of multiple PTB biomarkers, CRF, TNF, and TAT from depleted human blood
serum in 3D printed devices. A GMA monolith was modified with multiple antibodies to extract
and enrich the PTB biomarkers from human blood serum. The equilibrium dissociation constant
for each monoclonal antibody toward its target PTB biomarker was determined. PTB biomarker
retention conditions were optimized for successful extraction. The PTB biomarkers were then
selectively retained on these multiplexed antibody columns. This work yields promising steps
towards purifying all nine PTB biomarkers from human blood serum as an important process in a
complete diagnostic.
Chapter 5 summarizes the work in this dissertation and provides insightful suggestions
for future directions to advance the work for PTB risk detection with 3D printed microfluidic
devices.
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2. IMMUNOAFFINITY MONOLITHS FOR PEPTIDE EXTRACTION FROM
BLOOD SERUM IN 3D PRINTED MICROFLUIDIC DEVICES
2.1 Introduction
Preterm birth (PTB) is birth that occurs prior to week 37 of pregnancy. It is the most
common type of complication in pregnancy with an incidence rate of 1 out of every 9 births in
the United States.1-4 PTB is also a contributing cause in most neonatal deaths. Preterm infants
can have multiple problems throughout their lives such as hearing and vision loss, acute
respiratory failure, behavioral problems, sensory difficulty, and chronic lung disease.5 No
clinical methods are currently available to evaluate PTB risk at an early stage in pregnancy when
intervention can still delay delivery. Thus, there is a major need for an inexpensive and rapid
diagnostic method that can accurately evaluate the risk of PTB. Recently, nine maternal serum
PTB biomarkers were identified that show significant predictive power for the onset of early
labor.3
Due to their micro-scale dimensions (<100 µm), microfluidic devices offer multiple
advantages over conventional laboratory instrumentation. Microfluidic devices use lower
volumes of sample and reagents, making them ideal for handling costly or toxic chemicals.6
Moreover, the small size of microfluidic devices results in faster analysis times, better
temperature control, lower energy consumption, and portability.7 All these benefits make
microfluidic devices a promising platform for sensitive and cheap analysis. Originally,
microfluidic devices were fabricated using photolithography in silicon or glass. This method
requires multiple costly and complicated processes, including patterning, bonding, and etching
steps,8-9 so alternative techniques to overcome these limitations are needed.10
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Polydimethylsiloxane (PDMS) and thermoplastics are commonly used materials to create
microfluidic devices. PDMS is easy to mold and prototype, biocompatible, and optically clear.
These features make it an attractive material for use in many different experiments.11- 12
However, PDMS is easily torn during fabrication and is prone to nonspecific adsorption.13
Thermoplastics are another useful fabrication material because they can be optically clear,
inexpensive, and easily batch fabricated.14 However, many have poor resistance to non-polar
solvents, and it can be challenging to bond multiple layers during the fabrication process.15-16
3D printing is an additive manufacturing process that creates 3D objects layer by layer
from a computer designed file.17 These features make this technology useful in many
applications like dentistry and the aerospace industry to create precise models, prototypes, and
patterns.18 3D printing has numerous advantages over traditional microfabrication techniques,
such as offering lower setup costs, not requiring a cleanroom environment, and using fewer toxic
chemicals.19, 20 Recently, 3D-printed microdevices have received attention due to the potential
for rapid, iterative optimization, where experimental data can provide feedback to improve
design.21 One type of 3D printing called stereolithography (SL) uses a liquid resin that is
photopolymerized one layer at a time through exposure to UV light. A customized SL 3D printer
built by Nordin’s group at BYU has been used to make 20 μm × 20 μm channels in complex
fluidic patterns.22
A monolith is a porous polymer, and these materials have been researched for more than
two decades, resulting in the development of many applications.23 Monoliths can have a high
flow rate, enhanced mass transfer resistance, and low backpressure compared to traditional
packed bead columns.24 Immunoaffinity monoliths have been used to retain target analyte in a
column. Kang et al.25 used affinity monoliths to carry out microfluidic immunoassays for H1N1
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influenza virus. Furthermore, Parker et al.26 used an affinity monolith to extract ferritin, a PTB
biomarker, from human blood serum.
Here I have further developed immunoaffinity columns to extract CRF, a peptide PTB
biomarker, in a 3D printed device. I 3D printed 45 μm × 50 μm enclosed microfluidic channels
for immunoaffinity extraction. I used vacuum driven flow to extract CRF on an anti-CRF
monolith column. First, I demonstrated the binding between CRF and anti-CRF using a dot blot.
Next, I fluorescently labeled the anti-CRF and verified its attachment to the monolith using CCD
images. Lastly, I used an anti-CRF monolith column to extract CRF from both buffer and spiked
blood serum. My data show successful retention and elution of CRF from anti-CRF column. This
is the first demonstration of extracting a PTB peptide from human blood serum using a 3Dprinted microfluidic device. This study further shows the strong promise for using these
immunoaffinity columns to extract all nine PTB biomarkers from blood serum as part of a PTB
diagnostic system.
2.2 MATERIALS AND METHODS
2.2.1 Chemicals
Anti-corticotropin releasing factor (anti-CRF, produced in rabbit), glycidyl methacrylate
(GMA), ethylene glycol dimethacrylate (EDMA), 1- dodecanol, 2,2-dimethoxy-2phenylacetophenone (DMPA), poly (ethylene glycol) diacrylate (PEGDA, MW 250), Tris
hydrochloride, 3-(trimethoxysilyl) propyl methacrylate, dimethyl sulfoxide (DMSO), and
phenylbis (2,4,6 trimethylbenzoyl) phosphine oxide (Irgacure 819) were purchased from Sigma
(St. Louis, MO). Amicon ultra 0.5-mL centrifugal filters (3, and10 kDa cutoff), boric acid,
sodium phosphate, sodium bicarbonate, and sodium carbonate were obtained from Millipore
Sigma (Burlington, MA). Solutions were made using deionized water (18.3 MΩ) filtered by a
18

Barnstead EASY- pure UV/ UF system (Dubuque, IA). Alexa Fluor 532 (carboxylic acid,
succinimidyl ester) and Tris base were purchased from Fisher Scientific (Fair Lawn, NJ).
Isopropyl alcohol (IPA) was from Macron (Center Valley, PA). Sodium hydroxide was obtained
from Mallinckrodt Baker (Paris, KY). Glass slides for 3D printing were purchased from VWR
(Radnor, PA). Cyclohexanol was obtained from Spectrum (New Brunswick, NJ). 2-Nitrophenyl
phenyl sulfide (NPS) came from TCI (Portland, OR). Dry milk was purchased from Walmart
(Bentonville, AR). Nitrocellulose paper was obtained from Bio-Rad (Hercules, CA), and labeled
secondary antibody (IRDye 800CW goat anti-rabbit IgG came from LICOR (Lincoln, NE). CRF
came from GeneScript (Piscataway, NJ), and PTB peptide 2 (P2) was purchased from Biomatik
(Wilmington, DE). Female human blood serum (off-the-clot, sterile filtered) was purchased from
Zen-Bio (Research Triangle Park, NC).
2.2.2 3D Printed Microfluidic Devices
I used a custom 3D printer22 to create the design shown in Figure 2.1A-B. The design has
five separated channels, each 5 layers high and 6 pixels wide (50 μm x 45 μm), with a reservoir
on one end and a port in the other end to connect to vacuum. Devices also have a window for
polymerization of the monolith that is 600 μm wide and 6 layers above the channel.26 The
material used for fabricating 3D printed devices is 97% PEGDA, 2% NPS UV absorber, and 1%
Irgacure 819 photoinitiator.
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Figure 2.1 3D printed devices for affinity extraction. (A) OpenSCAD design. Reservoirs are yellow,
channels are green, the monolith polymerization window is blue, and the device divisions are red (B)
Cross section of device design. (C) Diagram of device operation for peptide extraction. The labeled
peptide is flowed through the channel by applying vacuum; as labeled analyte passes the detection point,
the signal is recorded. (D) Photograph of 3D printed device.

2.2.3 Sample Preparation
CRF and peptide 2 were fluorescently labeled by dissolving in 10 mM bicarbonate buffer
(BCB, pH 10). Alexa Fluor 532 was dissolved in DMSO and added to each biomarker. CRF (200
μM) and peptide 2 (40 μM) were labeled in 10 mM BCB pH 10 at a dye:biomarker molar ratio of
3:2 at room temperature overnight. Next, peptide 2 was filtered four times at 14,000 RPM for 15
min using an Amicon 3-kDa cutoff filter to remove excess dye. Then, samples were diluted to
the desired concentration in 20 mM phosphate buffer at pH 7. The anti-CRF was labeled at a
dye:antibody molar ratio of 10:1, and sample was filtered four times at 14,000 RPM for 15 min
using an Amicon 10-kDa cutoff filter to remove excess dye. The spiked CRF sample was
prepared by adding labeled CRF to yield a 300 nM concentration in human blood serum, which
was five-fold diluted in 20 mM phosphate buffer, pH 7.

20

2.2.4 Monolith Formation
Monoliths were prepared as described by Parker et al.26 using 24% GMA, 11% EDMA,
10% cyclohexanol and 55% 1-dodecanol. The solution was sonicated for 10 min, 1% DMPA
photoinitiator was added, and the mixture was sonicated for an additional 10 minutes. Then, the
mixture was allowed to fill the channels by capillary action, and the entire device was exposed to
UV light (SunRay 600, Uvitron, West Springfield, MA) for 10 min, which polymerized the
monolith at the desired location in the channel through the polymerization window built into the
design. The unpolymerized mixture was removed from the monolith by flushing the channels
with IPA for 30 min using vacuum.
2.2.5 Antibody characterization and immobilization
A dot blot experiment was performed to test the compatibility of anti-CRF toward CRF.
First, 2 μL of CRF (1 mg/mL) was dotted on nitrocellulose paper. After drying the dot for 30
min, a blocking step was performed using 5% milk in 10× Tris buffer saline (TBS) for 1 h to
block the rest of the paper. Next, the paper was submerged in antibody solution (1 μg/mL in TBS
plus 0.05 % Tween 20; TBST) and incubated for 1 h on a rotator. Then, the paper was washed
thoroughly using TBST for 15 min, and the secondary antibody (1 μg/mL in TBS) for
fluorescence detection was added and incubated for 1 h. Next, the paper was washed again with
TBST for 15 min. Finally, scans of dot blots were taken using a LI-COR ODYSSEY imaging
system.
To attach antibody to the monolith, 4 µL of solution (9.5 mg/mL) was added to the
device reservoir and allowed to flow through the monolith by capillary action. Then, the
reservoirs were filled with 20 mM borate buffer (pH 8) and sealed to prevent evaporation.
Devices were incubated for 7 h at room temperature in a humid chamber to provide sufficient
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time for primary amines on the antibody to react with epoxy groups on the GMA monolith. Next,
the remaining epoxy groups in the monolith were blocked by flowing 0.1 M Tris buffer (pH 8.5)
through for 1 h. After blocking, the monoliths were thoroughly washed with 20 mM phosphate
buffer (pH 7). For control experiments no antibody was added, but the monolith was blocked
using Tris buffer. I applied vacuum as shown in Figure 2.1C to move analytes in 3D printed
devices.
The attachment of anti-CRF to a GMA monolith was verified using CCD fluorescence
images. I directed a 532 nm laser through a 4X objective and took CCD images with 300 ms
exposure times. First, an image of the monolith was taken before attaching the antibody. Then,
anti-CRF labeled with Alexa Fluor 532 was immobilized onto the monolith overnight. Then, the
monolith was rinsed with 20 mM borate buffer pH 8 for 30 min and another image was taken of
the monolith. Image J was used to measure the background-subtracted fluorescence of the
monolith with labeled antibody compared to the control.
2.2.6 Experimental Setup
Experimental conditions followed those found in a published paper.26 I used a 532 nm
laser to induce fluorescence. The signal was recorded with a photomultiplier tube and digitized
using LabVIEW software. Experiments were conducted as follows. First, channels were filled
with 20 mM phosphate buffer pH 7, and vacuum was applied for 1 min through the device port
to equilibrate as seen in Figure 2.1C. Then, vacuum was removed, the reservoir was emptied and
fluorescently labeled sample was loaded into the reservoir and channel by applying vacuum for
one additional minute. The labeled sample was incubated on the monolith for 10 min, the
reservoir was washed three times with phosphate buffer, and the monolith was rinsed using 20
mM phosphate buffer (pH 7) for 6 min for sample loaded in buffer and 8 min for blood serum.
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Finally, reservoirs were filled with 50 mM bicarbonate buffer (pH 10) and vacuum was applied
for 1 min to elute the sample.
2.3 RESULTS AND DISCUSSION
2.3.1 Dot Blot Tests
I used a dot blot to confirm the compatibility of CRF toward anti-CRF, as seen in Figure
2.2. Figure 2.2A shows two fluorescence dots for a positive control of ferritin and anti-ferritin,
demonstrating the binding between the ferritin and anti-ferritin. Figure 2.2B shows two similar
bright fluorescent dots, indicative of strong binding of CRF to anti-CRF. These dot blots show
that the anti-CRF antibody chosen is suitable for CRF.

Figure 2.2 Dot blot assay on nitrocellulose membrane. Two duplicate dots of (A) positive control with
ferritin and anti-ferritin; and (B) CRF and anti-CRF.

2.3.2 Immunoaffinity Monoliths in 3D Printed Devices
The 3D printed devices are seen in Figure 2.1D. My devices match the design files in
Figure 2.1A-B with five independent channels. I successfully formed monoliths inside my 3D
printed devices as seen in Figure 2.3A. The morphology of the GMA monoliths was determined
using scanning electron microscopy (SEM) as seen in Figure 2.3B-C. Monolith pore and nodule
sizes were analyzed using ImageJ, and were 1.5 ± 0.6 μm (n=50) and 0.49 ± 0.08 μm (n=50),
respectively. The SEMs images show that my monoliths were well polymerized and anchored to
the microfluidic channel wall. This wall attachment is essential for good flow and analyte
interaction with the monolith.
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Figure 2.3 Formation of a monolith in a 3D printed microfluidic device. (A) Photograph of monolith
inside a channel. (B-C) SEM images of monoliths prepared from GMA with 10-min exposure in a 3D
printed microfluidic device; (B) channel view and (C) zoom view.

To verify the attachment of anti-CRF to a GMA monolith, I used fluorescence imaging.
A fluorescence image of a monolith before attaching the antibody is shown in Figure 2.4A. A
monolith after attachment of AlexaFluor 532 labeled anti-CRF and rinsing is seen in Figure
2.4B. The fluorescence on the control monolith in Figure 2.4A is much dimmer compared to the
monolith that had the fluorescently labeled anti-CRF attached. These images show differences
between the control monolith and the antibody-modified monolith, clearly indicating that antiCRF was successfully attached to the GMA monolith. Figure 2.4C shows the backgroundsubtracted fluorescence measurement for the monolith with labeled antibody compared to the
control. The fluorescence signal was significantly increased compared to the blank, confirming
that anti-CRF was attached to the monolith.
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Figure 2.4 Labeled antibody attachment. Fluorescence images of (A) control and (B) labeled anti-CRF
fluorescence monoliths. (C) Background-subtracted fluorescence of the monolith before and after
immobilization of labeled anti-CRF.

2.3.3 Immunoaffinity Extraction of CRF Using 3D Printed Microfluidic Devices
I studied CRF retention and elution when there was no antibody on the monolith, and
when anti-CRF was immobilized on the monolith as seen in Figure 2.5. In both experiments,
labeled CRF in either buffer or blood serum was loaded into the channel, which caused an
increase in the fluorescent signal on the monolith. After rinsing nonspecifically bound labeled
analyte from the monolith, the fluorescent signal on the monolith drops. Upon eluting,
fluorescence on the monolith further decreases, confirming that retained CRF on the anti-CRF
monolith was removed.
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Figure 2.5 Fluorescence signal from the monolith during the extraction of CRF from human blood serum
diluted five-folds and spiked with 300 nM CRF. (Blue) control monolith (no anti-CRF); (orange)
monolith with (anti-CRF).

Point detection of fluorescence after the monolith during elution (see Figure 2.1C)
showed a peak at 10 seconds for the anti-CRF column, compared to no peak observed from the
blocked monolith, as seen in Figure 2.6A. These results demonstrate successful elution of
retained CRF loaded from buffer using an anti-CRF monolith. I completed a similar experiment
using blood serum diluted 1:5 in buffer and spiked with CRF as seen in Figure 2.6B. A small
increase in fluorescence at five seconds was seen for both the anti-CRF and blocked columns.
This feature may arise from elution of nonspecifically adsorbed components present in the blood
serum. A much larger increase observed at 10 second was only seen for elution from the antiCRF monolith. This demonstrates elution of CRF selectively retained from spiked blood serum
in the anti-CRF column.
I also tested the selectivity of anti-CRF toward a different PTB peptide biomarker by
loading labeled peptide 2 on an anti-CRF column and eluting. As seen in Figure 2.6C
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fluorescence during elution showed narrow, small peaks at five seconds for both anti-CRF and
blocked columns. These peaks likely resulted from a minor amount of nonspecific adsorption of
peptide 2 to the monolith. These data confirm that the binding between CRF and anti-CRF
relative to the peptide 2 PTB biomarker in a 3D-printed device is selective.

Figure 2.6 Fluorescence elution profile on an anti-CRF monolith (red) or a control monolith lacking
attached antibody (blue) of (A-B) 300 nM AF532-labeled CRF from (A) buffer and (B) human blood
serum (diluted 5-fold), or (C) 150 nM AF532-labeled peptide 2.

I used a custom 3D printer to create microfluidic devices with immunoaffinity monoliths
for selective retention and elution of CRF from human blood serum. These 3D-printed devices
are easy to prototype and can make 3D microfluidic features. This is the first demonstration of an
immunoaffinity column in a 3D-printed device for extraction of a peptide biomarker from both
buffer and blood serum. This study is an important step towards the goal of multiplexed analysis
of PTB biomarkers from serum in a single 3D printed microfluidic device.
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3. CHARCTERIZATION OF ANTIBODIES TARGETING PTB BIOMARKERS
FOR IMMUNOAFFINITY EXTRACTION
3.1 Introduction
Finding a compatible antibody to target an antigen is essential in immunoaffinity assays.
The binding between antigen and antibody is influenced by non-covalent intermolecular
interactions such as hydrogen bonding, electrostatic interactions, hydrophobic interactions, and
Van der Waals forces between the two molecules.1
Antibodies are produced from B cells and can be either polyclonal or monoclonal.2-3
Polyclonal antibodies have the affinity to recognize their target antigen as well as similar epitopes
if the epitope has a sequence match to the antibody. However, monoclonal antibodies are highly
specific and only recognize a specific epitope. Identifying specific antibodies for PTB biomarkers
facilitates immunoaffinity extraction. Cross reactivity can occur when the antibody has affinity to
bind to multiple antigens. This phenomenon is often observed in polyclonal antibodies that contain
a heterogeneous mixture of antibodies produced from different B cells.4
Dot blotting is a rapid technique that is widely used to examine compatibility between
antigen and antibody. Antigen-antibody interactions are more precisely measured by traditional
techniques such as ELISA,5-7 radioimmunoassay,8 or isothermal titration calorimetry.9 Although
these techniques are effective, they are also time consuming, require labeled samples, and are
expensive.10 However, alternative methods are now available to study the interaction between
molecules,11 which are label free, high throughput, and fast.12-13 Two common biosensor
techniques are BLI and SPR.12-15 Both are widely used, generate quick results, and provide
quantitative data to study the intermolecular interaction between antigen-antibody complexes.
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Understanding the mathematical basis of the interaction between the antigen-antibody
complex is significant for the quality of an immunoassay. The equilibrium between the antibody
(Ab) and antigen (Ag) is reversible, and generates the antibody-antigen complex (Ab-Ag), which
is expressed via equation (3.1).2
[Ab]+[Ag] ⇌ [Ab-Ag]

(3.1)

The association and dissociation constants are represented by Ka and Kd, respectively.

[Ab] is the antibody concentration, [Ag] is the antigen concentration, and [Ab-Ag] is the
concentration of complex in the bound state. Ka and Kd are calculated as shown in equations
(3.2) and (3.3).
Ka = kon / koff = [Ab-Ag] / [Ab][Ag]
Kd = koff / kon = [Ab][Ag] / [Ab-Ag]

(3.2)
(3.3)

The closer Kd is to zero, the tighter the binding in the Ab-Ag complex and the more stable
the interaction between the complex will be. The value of Kd corresponds to the concentration of
the ligand at which half of the antigen is saturated at equilibrium. Knowing Kd values helps to
determine which analyte will dissociate more readily from a multiplex antibody column, based
on which has the strongest or weakest interaction with its target. This information is needed for
extraction of all nine PTB biomarkers from human blood serum.
Determination of the strength of binding between PTB biomarkers and their targeted
antibodies is a significant step in the development of multiplex immunoaffinity columns. In this
chapter, I present the data for either monoclonal or polyclonal antibody characterization, cross
reactivity for multiple PTB biomarkers, and outcomes of immunoaffinity extraction. BLI of
several PTB biomarkers, ferritin, lactoferrin, and CRF, toward their polyclonal antibodies is also
reported.
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3.2 MATERIALS AND METHODS
3.2.1 Reagents
Ferritin was obtained from EMD Millipore (Billerica, MA). Lactoferrin, anti-lactoferrin
(produced in rabbit), anti-ferritin (produced in rabbit), and anti-corticotropin releasing factor (antiCRF, produced in rabbit) were purchased from Sigma (St. Louis, MO). CRF came from GenScript
(Piscataway, NJ). PTB, peptide 2, and peptide 3, and biotinylated CRF were purchased from
Biomatik (Wilmington, DE). Sodium phosphate was obtained from Millipore Sigma (Burlington,
MA). Alexa Fluor 532 (carboxylic acid, succinimidyl ester) and Tris base were purchased from
Fisher Scientific (Fair Lawn, NJ). EZ-Link Sulfo-NHS-LC-Biotin, monoclonal anti-CRF
(produced in mice), and both polyclonal and monoclonal anti-ITIH4 were obtained from
ThermoFisher (St. Louis, MO). Dry milk was purchased from Walmart (Bentonville, AR).
Nitrocellulose paper was obtained from Bio-Rad (Hercules, CA), and IRDye 800CW labeled
secondary goat anti-mouse IgG came from LICOR (Lincoln, NE). Streptavidin biosensors were
purchased from ForteBio (Fermont, CA) and bovine serum albumin (BSA) was purchased from
EMD Millipore. Assay workflow details are described in Chapter 4.1.7.
3.2.2 PTB Biomarker Preparation for Immunoaffinity Extraction
The PTB biomarkers were all fluorescently labeled and included ferritin, lactoferrin,
TNF, peptide 2 and CRF dissolved in 10 mM bicarbonate buffer (BCB, pH 10). TAT was
prepared as in Nielsen et al.16 Alexa Fluor 532 was dissolved in DMSO, added to each
biomarker, and incubated at room temperature overnight. Peptide 2 was heated at 37°C during
labeling. All PTB biomarkers were labeled at the different dye:biomarker molar ratios shown in
Table 3.1. Next, protein biomarkers were filtered four times at 14,000 RPM for 15 min using a
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cutoff filter depending on their size. Samples were diluted to the desired concentration in 20 mM
phosphate buffer pH 7 for ferritin, lactoferrin, TNF, and CRF, or at pH 8 for peptide 2. Peptide 2
was also spiked into human blood serum to a 500 nM concentration.
Table 3.1 Dye: PTB biomarker molar labeling ratio.

3.2.3 Antibody Characterization and Immobilization
A dot blot experiment was performed to test the compatibility of either polyclonal or
monoclonal antibodies toward PTB biomarkers as described in Chapter 2.5.
3.2.4 Immunoaffinity Experimental Setup
Experimental conditions are described in Chapter 2.6. Briefly, I used a 532 nm laser to
induce fluorescence. First, channels were filled with either 20 mM phosphate buffer pH 7 or pH
8, and vacuum was applied through the device to move the PTB analyte. The labeled sample was
incubated on the monolith for 10 min, followed by three washes with phosphate buffer. Finally,
reservoirs were filled with 50 mM bicarbonate buffer (pH 10) and vacuum was applied for 1 min
to elute the sample.
3.2.5 Kinetic Characterization
Ferritin and lactoferrin were dissolved in PBS pH 7 (at the concentration of 1 mg/mL)
and then biotinylated as described in the ThermoFisher protocol for product No. A39257. CRF
was synthesized with a biotin label at one end and then dissolved in PBS pH 7 at 1 mg/mL. All
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biomarkers (CRF, ferritin, and lactoferrin) were loaded on the biosensor at 5-10 μg/mL. The
association step was performed for 400 s for anti-CRF, 300 s for anti-ferritin, and 60 s for antilactoferrin for the different concentrations. The dissociation step was performed in the assay
buffer for 800 s for CRF, 300 s for anti-ferritin, and 800 s for anti-lactoferrin in PBS pH 7. The
BLI data for association and dissociation were analyzed by Octet Data Analysis 8.2 software and
fit to a 1:1 binding model to obtain kinetic parameters.
3.3 Results and Discussion
3.3.1 Characterization of Polyclonal Antibodies Targeting PTB Biomarkers
Dot blots were used to evaluate binding of specific polyclonal antibodies to target PTB
peptide biomarkers. Dot blots of polyclonal antibodies against ITIH4 (to target peptides 2 and 3)
are shown in Figure 3.1, in addition to fluorescence dots for the lactoferrin and anti-lactoferrin
positive control. These dot blots clearly show that the polyclonal antibodies selected are suitable
for the PTB peptide biomarkers of peptide 2 and peptide 3.

Figure 3.1 Dot blot assays on nitrocellulose membranes for polyclonal antibodies. Fluorescent dots of
(A) positive control with lactoferrin and anti-lactoferrin, (B) peptide 2 and anti-ITIH4, and (C) peptide 3
and anti-ITIH4.

To extract multiple PTB biomarkers, I first developed individual immunoaffinity columns
in a 3D printed microfluidic device for the extraction of two PTB biomarkers: CRF, and
lactoferrin. Extraction of CRF using polyclonal anti-CRF is discussed in chapter 2. Elution of
lactoferrin from its polyclonal antibody is seen in Figure 3.2, which shows an elution peak at 20
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seconds from lactoferrin on an anti-lactoferrin column compared to a much smaller peak for the
blocked column. This peak on the control column is a result of adsorption of lactoferrin. These
data show successful retention and elution of another PTB protein biomarker, which combined
with CRF extracted in Chapter 2, and ferritin extracted by Parker et al.,17 is a further step toward
extraction of all nine PTB biomarkers.

Figure 3.2 Fluorescence during elution after extraction of 50 nM AF532-labeled lactoferrin in 20
mM phosphate buffer pH 7 from a polyclonal antibody-modified column (red) or a control monolith
lacking attached antibody (blue).

3.3.2 Selectivity of PTB Biomarker Extraction in Immunoaffinity Columns
To achieve successful capture of all nine PTB biomarkers using their respective polyclonal
antibodies, I conducted an experiment to check whether there is cross reactivity between any of
PTB biomarkers and off-target polyclonal antibodies using dot blots. Figure 3.3A shows
fluorescent dots for ferritin and anti-ferritin as a positive control. Figure 3.3B shows fluorescent
dots for ferritin on a non-target polyclonal antibody, anti-CRF, which indicates some cross
reactivity between ferritin and anti-CRF polyclonal antibody. Figure 3.3C represents fluorescent
dots for lactoferrin and anti-CRF, which indicates more cross reactivity. This high cross
reactivity possibly resulted from adsorption of lactoferrin to the primary antibody. Figure 3.3D
shows no fluorescence, which means no off-target binding was observed between CRF and
polyclonal anti-ferritin. This could be due to the small size of the peptide that makes it hard to
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recognize and bind to a non-target antibody. These data show off-target binding between PTB
protein biomarkers, ferritin and lactoferrin, with polyclonal anti-CRF.

Figure 3.3 Dot blot assays on nitrocellulose membranes for polyclonal antibodies. Four duplicate
dots of (A) positive control with ferritin and anti-ferritin. (B) ferritin and anti-CRF. (C) lactoferrin
and anti-CRF. (D) CRF and anti-ferritin.

Another experiment was conducted to confirm the cross reactivity that was observed from
polyclonal antibodies in dot blots. Fluorescently labeled ferritin was loaded on anti-lactoferrin
column. Figure 3.4A shows an elution peak at 50 seconds for ferritin on the anti-lactoferrin column.
However, when CRF was loaded on non-target polyclonal antibody column, no elution peak was
detected, as seen in Figure 3.4B. This data shows no off-target binding observed between CRF and
polyclonal anti-ferritin. To conclude, off-target interaction between PTB protein biomarkers and
polyclonal antibodies occurs, but limited interaction is seen between PTB peptide biomarkers and
non-target polyclonal antibodies. Although polyclonal antibodies have the ability to capture their
target antigens effectively, I observed cross reactivity between PTB protein biomarkers and offtarget antibodies. This is likely due to their ability to recognize multiple epitopes on different
antigens. The cross reactivity between polyclonal antibodies and non-target analytes hindered the
development of multiplex immunoaffinity extraction.
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Figure 3.4 Fluorescence elution profiles of (A) 50 nM AF532-labeled ferritin on a polyclonal antilactoferrin column and (B) 300 nM AF532-labeled CRF on a polyclonal anti-ferritin column.

3.3.3 BLI of PTB Biomarkers and Their Target Polyclonal Antibodies
Even with the observed cross reactivity issues, I decided to obtain Kd data for three PTB
biomarkers with their polyclonal antibodies. Figure 3.5 shows the fitting curves for association
and dissociation for ferritin, lactoferrin, and CRF and their respective polyclonal antibodies at
different concentrations. The Kd values for the three PTB biomarkers were calculated for their
polyclonal antibodies as seen in Table 3.2. These data show that, of these three, lactoferrin has
the strongest binding affinity toward its anti-lactoferrin antibody, and CRF has the lowest
binding affinity toward anti-CRF. If these three biomarkers are loaded together onto a
multiplexed affinity column, I expect that CRF should dissociate more readily from its target,
followed by ferritin and then lactoferrin.
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Figure 3.5 BLI association and dissociation data and fitting for ferritin, lactoferrin, and CRF
binding to their respective polyclonal antibodies. (A) Anti-ferritin, (B) anti-lactoferrin and (C) antiCRF at different concentrations. The red curves are the antibody with different concentrations and
the blue curves are the control reference.

The Kd values in Table 3.2 are in the nanomolar range for ferritin, lactoferrin, and CRF, as
expected for polyclonal antibodies.18 For lower affinity antibodies (higher Kd), it may be difficult
to detect the antigen if present at a low concentration in serum. For example, the PTB risk level in
blood serum for ferritin is 0.040 nM, which is more than 200x lower than the Kd of polyclonal
anti-ferritin (10 nM). To effectively extract ferritin from blood serum at PTB risk levels, I will
need to increase the antibody concentration or increase the affinity. One way to access lower
biomarker concentrations would be to alter the Kd by using another antibody that has higher
affinity to the antigen. This same approach can be applied for the rest of the PTB biomarkers.
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Table 3.2 Calculated Kd values of polyclonal anti-ferritin, anti-lactoferrin, and anti-CRF binding to
ferritin, lactoferrin, and CRF via BLI assay.

3.4. Characterization of Monoclonal Antibodies
Because there was cross reactivity between PTB biomarkers and off-target polyclonal
antibodies, I conducted dot blot analysis for monoclonal antibodies. Monoclonal antibodies have
the ability to recognize a specific epitope on the antigen, so I expected no cross reactivity
between PTB biomarkers and off-target antibodies.
Figure 3.6 shows three replicates dot blots in each panel. Figure 3.6A is a positive control
between ferritin and anti-ferritin. Figure 3.6B shows binding between ferritin and a monoclonal
ferritin antibody, while Figure 3.6C shows interaction between lactoferrin and monoclonal antilactoferrin. Figure 3.6D displays fluorescent dots for peptide 2 and anti-ITIH4, which indicates
binding between them. Similarly, Figure 3.6E demonstrates binding between peptide 3 and antiITIH4. These dot blots show successful binding between monoclonal antibodies and their
respective PTB biomarkers, which makes them a great choice to use in immunoaffinity
extraction.
Cross reactivity was further studied between ferritin and lactoferrin toward off target
monoclonal antibodies. No binding was observed between ferritin and monoclonal antilactoferrin as seen in Figure 3.6F. In Figure 3.6G, no fluorescence was observed between
lactoferrin and monoclonal anti-ferritin. No fluorescent dots were seen in either Figure 3.6H or I
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when ferritin was dotted on either monoclonal anti-CRF or monoclonal anti-TNF. The lack of
cross reactivity gives additional support to the ability to use these monoclonal antibodies for
multiplex immunoaffinity experiments.

Figure 3.6 Dot blot assays on nitrocellulose membranes for monoclonal antibodies. Three duplicate dots
of (A) positive control with ferritin and anti-ferritin. (B) Ferritin and mAb anti-ferritin. (C) Lactoferrin
and mAb anti-lactoferrin. (D) Peptide 2 and anti-ITIH4. (E) Peptide 3 and anti-ITIH4. (F) Ferritin and
mAb anti-lactoferrin. (G) Lactoferrin and mAb anti-ferritin. (H) Ferritin and mAb anti-CRF. (I) Ferritin
and mAb anti-TNF.

3.5 Immunoaffinity Extraction of PTB Biomarkers Using Monoclonal Antibodies
After I characterized monoclonal antibodies to ferritin, lactoferrin, peptide 2, and peptide
3 and verified the lack of off-target binding, I developed individual immunoaffinity columns for
extraction of three of these PTB biomarkers in 3D printed microfluidic devices. These studies lay
the foundation for subsequent extraction of multiple PTB biomarkers on a multiplexed
immunoaffinity column. Figure 3.7A-B each shows an elution peak at 20 seconds for ferritin and
lactoferrin from their respective monoclonal antibody column compared to a blocked column.
Ferritin has a narrow and taller peak on the affinity column compared to the blocked column. In
contrast, lactoferrin shows a wider peak and a little increase in the fluorescence at 10 seconds,
which may indicate adsorption of lactoferrin to the monolith. Figure 3.7C shows a slightly taller
and wider elution peak that appears at 20 seconds for peptide 2 loaded from buffer on an antiITIH4 column, compared to the narrower signal observed on a control column. Figure 3.7D
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shows a wider elution peak that appears at 60 seconds for loaded peptide 2 spiked in blood serum
for an antibody column, compared to little elution seen for the same sample loaded on a blocked
monolith. These data indicate successful retention and elution of two PTB protein biomarkers,
ferritin and lactoferrin from buffer, as well as successful elution of peptide 2 from anti-ITIH4
column when loaded from either buffer or blood serum.
Only a little off-target binding was seen when the PTB biomarker ferritin was loaded on
either monoclonal anti-lactoferrin or anti-TNF, as seen in Figure 3.8A-B. This binding may result
from non-specific adsorption from ferritin to the immunoaffinity column, and not from binding of
ferritin to off-target monoclonal antibodies, consistent with dot blot data in Figure 3.6.
These experiments show successful development of immunoaffinity columns for PTB biomarker
extraction from their respective monoclonal antibodies. Monoclonal antibodies for three other
PTB biomarkers, CRF, TNF, and TAT are further characterized, immobilized, and used for
multiplexed extraction from a single immunoaffinity column as discussed in chapter 4.
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Figure 3.7 Fluorescence during elution after extraction of AF532-labeled PTB biomarkers from a
monoclonal antibody-modified column (red) or a control monolith lacking attached antibody (blue) for
(A) 50 nM ferritin and (B) 100 nM lactoferrin in 20 mM phosphate buffer pH 7, or (C) 500 nM peptide 2
in either (C) buffer or (B) human blood serum diluted 5-fold in phosphate buffer pH 8.

Figure 3.8 Fluorescence elution profiles of (A) 50 nM AF532-labeled ferritin on a monoclonal antilactoferrin and (B) a monoclonal anti-TNF column.
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3.6 Conclusions
I was successful in finding polyclonal antibodies to target multiple PTB biomarkers. I
also developed a polyclonal immunoaffinity column to extract the PTB protein biomarker
lactoferrin, in a 3D printed microfluidic device. I was able to test cross reactivity between PTB
biomarkers and multiple off-target polyclonal antibodies. Substantial off-target binding between
PTB protein biomarkers and polyclonal antibodies was seen, while a lack of off-target interaction
was observed between PTB peptide biomarkers and polyclonal antibodies.
I used a BLI assay to study the binding affinity between ferritin, lactoferrin, and CRF and
their polyclonal antibodies. The Kd values calculated were in the nanomolar range as expected
for polyclonal antibodies.18 Measuring the Kd values for the remaining PTB biomarkers will
allow us to determine which of the biomarkers dissociates more readily from its target in a
multiplexed immunoaffinity experiment. High affinity antibodies will increase my ability to
easily target PTB biomarkers at lower concentrations in blood serum.
Initial experiments with monoclonal antibodies showed good binding affinity with their
target biomarker and no off-target binding between any of the studied PTB biomarkers and
monoclonal antibodies. This makes them an ideal option for extracting multiple PTB biomarkers
in a multiplex immunoaffinity column. I found compatible monoclonal antibodies for ferritin,
lactoferrin, peptide 2, and peptide 3. I also developed an immunoaffinity column to retain and
extract three PTB biomarkers, ferritin, lactoferrin, and peptide 2 using their monoclonal
antibodies in 3D printed microfluidic devices. Building further on work described in Chapter 4,
in the future it may be possible to immobilize monoclonal antibodies for all nine PTB
biomarkers in immunoaffinity columns and extract PTB biomarkers from human blood serum.
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4. IMMUNOAFFINITY MONOLITHS FOR MULTIPLEXED EXTRACTION OF
PRETERM BIRTH BIOMARKERS FROM HUMAN BLOOD SERUM IN 3D
PRINTED MICROFLUIDIC DEVICES*
4.1 Introduction
Multiplexed assays are important for drug screening,1 cytotoxicity,2 and biomarker
detection.3-4 Biomarkers can serve as indicators for the presence of disease, but are usually
present in low concentrations in blood serum.5 Particularly, because blood serum contains up to
50 g/L of albumin and immunoglobulins,6 these matrix components can interfere with biomarker
analysis, making biomarker detection a challenging endeavor.7
Risk for a preterm birth (PTB), defined as birth prior to 37 weeks of gestation, can be
correlated with a panel of nine biomarkers found in maternal blood serum.8 These biomarkers
include four proteins and five peptides, and allow for prediction of PTB risk with 87% selectivity
and 81% specificity. However, detecting these biomarkers from human blood serum is
challenging due to their very low concentrations relative to other proteins in serum. To achieve
successful early diagnosis of PTB risk, there is a need for effective and rapid sample preparation
methods to address these issues.

∗ This chapter is adapted from:
Almughamsi, H. M.; Howell, K. M.; Parry, S. R.; Esene, J. E.; Nielsen, J. B.; Nordin, G. P.;
Woolley, A. T. Immunoaffinity Monoliths for Multiplexed Extraction of Preterm Birth
Biomarkers from Human Blood Serum in 3D Printed Microfluidic Devices. Analyst. Submitted
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An immunoaffinity column selectively retains analytes using antigen-antibody
interaction. This strong and selective interaction is desirable for purifying target biomarkers from
complex specimens. Porous polymer monoliths are useful in sample preparation9-11 and show
promise in immunoaffinity extraction of biomarkers in blood using one or more antibodies
attached to a column.12-13 The biophysical characteristics of antigen-antibody binding play a
significant role in immunoaffinity extraction. Understanding this interaction provides
information about the stability of binding, which is useful for development of multiplexed
immunoaffinity extraction. Biolayer interferometry (BLI)14 and surface plasmon resonance
(SPR)15 are powerful, label-free methods that are used to determine affinity binding strength
between antigen-antibody complexes.
Microfluidics is a promising platform for multiplex sample preparation. The small
amounts of sample and reagents needed can reduce costs and analysis time.16-17 3D printing of
microfluidic devices can overcome challenges associated with traditional fabrication techniques,
and can enable novel designs that are otherwise inaccessible.12,18-21 These 3D printed
microfluidic devices can be used to facilitate sample preparation and biomarker analysis. For
example, Bickham et al.19 used solid phase extraction monoliths to concentrate and label a panel
of nine PTB biomarkers. Although this is a good method for enriching and labeling samples,
PTB biomarkers have to be first purified from blood serum, which cannot be performed on this
type of monolith. Parker et al.12 purified ferritin from human blood serum as a step toward a PTB
risk diagnostic, but only one PTB biomarker was captured on a single-antibody column. Thus,
extending this approach to immobilize multiple antibodies and extract multiple PTB biomarkers
on a single immunoaffinity column would be advantageous for point-of-care testing.22
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Here, I overcome these earlier limitations with immunoaffinity columns to purify
multiple PTB biomarkers simultaneously from human blood serum in 3D printed microfluidic
devices. Immunoaffinity columns were modified with a mixture of monoclonal antibodies that
were initially evaluated using dot blots, BLI, and SPR. Selectivity of each biomarker toward its
respective antibody was first studied, and each biomarker was individually extracted from a
single-antibody column. I then selectively enriched three PTB biomarkers from blood serum
using multiplexed immunoaffinity monoliths in 3D printed microfluidic devices. This study is
the first use of a well-characterized, high-specificity immunoaffinity column that simultaneously
extracts several PTB biomarkers in a 3D printed microfluidic device. This is a key step toward
the future development of 3D printed microfluidic devices for rapid PTB risk assessment.
4.2 MATERIALS AND METHODS
4.2.1 Chemicals
Glycidyl methacrylate (GMA), ethylene glycol dimethacrylate (EDMA), 1-dodecanol,
2,2-dimethoxy-2-phenylacetophenone (DMPA), poly (ethylene glycol) diacrylate (PEGDA, MW
250), Tris hydrochloride, 3-(trimethoxysilyl) propyl methacrylate, dimethyl sulfoxide (DMSO),
phenylbis (2,4,6 trimethylbenzoyl) phosphine oxide (Irgacure 819), Amicon ultra 0.5-mL
centrifugal filters (10 and 50 kDa cutoff), boric acid, sodium bicarbonate, and sodium carbonate
were obtained from ThermoFisher (St. Louis, MO). Alexa Fluor 532 (carboxylic acid,
succinimidyl ester) and Tris base were purchased from Fisher Scientific (Fair Lawn, NJ).
Solutions were made using deionized water (18.3 MΩ) filtered by a Barnstead EASY-pure
UV/UF system (Dubuque, IA). Isopropyl alcohol (IPA) was from Macron (Center Valley, PA).
Cyclohexanol was obtained from Spectrum (New Brunswick, NJ). 2-Nitrophenyl phenyl sulfide
(NPS) came from TCI (Portland, OR). Amicon ultra-4 centrifugal filters (15 mL, 10 and 30 kDa
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cutoff), and 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) were purchased from
EMD Millipore (Billerica, MA). Glass slides for 3D printing were purchased from VWR
(Radnor, PA).

4.2.2 Biological Components
Corticotropin releasing factor (CRF) came from GenScript (Piscataway, NJ), and tumor
necrosis factor-α receptor type 1 (TNF) was purchased from ProSpec (East Brunswick, NJ).
Thrombin and antithrombin were obtained from Haematologic Technology (Essex Junction,
VT), and heparin was obtained from Alfa-Aesar (Haverhill, MA). Antibodies to thrombinantithrombin complex (anti-TAT, produced in mice) were purchased from Abcam (Cambridge,
MA). Anti-CRF (produced in mice), anti-TNF (produced in mice), EZ-Link Sulfo-NHS-LCBiotin, and high select top 14 abundant protein depletion midi spin columns were obtained from
ThermoFisher (St. Louis, MO). Dry milk was purchased from Walmart (Bentonville, AR).
Nitrocellulose paper was obtained from Bio-Rad (Hercules, CA), and IRDye 800CW labeled
secondary goat anti-mouse IgG came from LICOR (Lincoln, NE). Female human blood serum
(off-the-clot, sterile filtered) was purchased from Zen-Bio (Research Triangle Park, NC).
Streptavidin biosensors were purchased from ForteBio (Fremont, CA) and bovine serum albumin
(BSA) was purchased from EMD Millipore.
4.2.3 3D Printed Microfluidic Devices
The microfluidic devices (Figure 4.1A) were adapted from Bickham et al.19 and designed
to have five separated channels, each with a 50 μm x 45 μm cross section. Each channel had a
reservoir on one side of the device and a port in the other side for PTFE tubing (0.22 in ID x
0.042 in OD; Cole Parmer, Vernon Hills, IL) to connect to vacuum and flow analyte through the
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channel. A 600 μm wide monolith polymerization window (MPW) was designed in each device
to allow monolith polymerization.12 97% PEGDA, 2% NPS UV absorber, and 1% Irgacure 819
photoinitiator composed the resin used to fabricate the devices in a custom 3D printer.23

Figure 4.1 3D printed devices with monoliths for affinity extraction. (A) Photograph of 3D printed
device. (B) Photograph of monolith inside channel. (C-D) SEM images of monoliths prepared in a 3D
printed microfluidic device; (C) channel view and (D) zoom view. (E) Device schematic for PTB
biomarker extraction. The labeled biomarker flows through the channel via vacuum; as labeled analytes
pass the detection point, the signal is recorded.

4.2.4 PTB Biomarker Preparation
The PTB biomarkers were fluorescently labeled; CRF and TNF were dissolved in 10 mM
bicarbonate buffer (BCB, pH 10), and TAT was prepared as in Nielsen et al.24 Alexa Fluor 532
was dissolved in DMSO, added to each biomarker and incubated at room temperature overnight.
CRF (100 μM), TNF (40 μM), and TAT (26 μM), were labeled at a dye:biomarker molar ratio of
3:2, 20:1 and 20:1, respectively. Next, TNF and TAT were filtered four times at 14,000 RPM for
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15 min using a 10-kDa or 50-kDa cutoff filter, respectively, to remove excess dye. Samples were
diluted to the desired concentration in 20 mM HEPES buffer pH 7. To prepare depleted blood
serum, I followed the Thermo Fisher protocol for their columns (Cat No. A36371). Briefly, 100
μL of serum was added into a pre-filled midi spin column that contained 1000 μL of a 50%
slurry in 10 mM PBS, 0.02% sodium azide, pH 7.4. Then, the column was gently inverted to
form a homogenous mixture, which was incubated in the column for 10 min with gentle
agitation. I placed the column in a 15 mL falcon tube and centrifuged the column at 1000 g for 2
min. Afterward, the depleted serum, now 10-fold diluted, was collected and stored at -20ºC until
further use. Labeled biomarker samples were spiked into the depleted serum to yield 100 nM
CRF, 30 nM TNF, and 60 nM TAT.
4.2.5 Kinetic Characterization
Kd values were calculated for CRF, TNF, and TAT with their respective monoclonal
antibodies. Assays were conducted using either Biacore (Creative Biolabs) SPR (CRF and TNF)
or an OCTET RED96 biolayer interferometer (ForteBio) in PBS pH 7 at 30 ºC with 1000 rpm
shaking (TAT). TAT was biotinylated as described in the ThermoFisher protocol for product No.
A39257. Then, the BLI assay was run on a standard microwell plate when the streptavidin
biosensors were loaded with the biotinylated TAT at 5-10 μg/mL at 300 s. Five sensors were
used, three for antibody binding, and two for the reference control. The loaded sensors were
equilibrated first with PBS pH 7 to generate the baseline. Then, the association step was
performed 30 s for different concentrations ranging from 62 to 250 nM. The dissociation step
was performed in the assay buffer for 800 s in PBS pH 7. The data for association and
dissociation were analyzed by Octet Data Analysis 8.2 software and fit to a 1:1 binding model to
obtain kinetic parameters. SPR data were obtained on samples shipped to Creative Biolabs.
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4.2.6 Monolith Formation
Modified monoliths were prepared as reported by Parker et al.12 using 24% GMA as the
monomer, 11% EDMA as cross linker, 10% cyclohexanol and 55% 1-dodecanol as porogens,
and 1% DMPA as the photoinitiator. The monolith mixture was sonicated for 10 min and loaded
into the microfluidic channel via capillary action. Then, the entire device was placed under a UV
light (SunRay 600, Uvitron, West Springfield, MA) for 10 min allowing the monolith to
polymerize at the desired channel location in the MPW. After polymerization, PTFE tubing was
inserted into the device port and hot glued in place. The unpolymerized mixture was removed
from the channel by flushing with IPA for 30 min using vacuum. Scanning electron microscopy
(SEM) images of the monolith were taken by removing the 3D-printed channel from the glass
slide using a razor blade. Then, the monoliths were cut through the MPW and affixed on stubs
using carbon tape. Next, 80:20 Au:Pd was sputter coated on the surface of the monolith using a
Q150 T ES Sputterer (Quorum Technologies, Lewes, East Sussex, UK). Finally, the SEM
images were taken using an Apreo C Low-Vacuum SEM instrument (Thermo) in high vacuum
mode at 10 kV.
4.2.7 Antibody Immobilization
Compatibility of the PTB biomarker antibodies towards their targets and off-target
analytes was tested using dot blots. Solutions of CRF, TNF, and TAT (2 µL, 1 mg/ml) were
dotted on nitrocellulose paper and left to dry for 30 min. Then, a blocking buffer of either 5%
milk, or 5% BSA in 10× Tris buffer saline (TBS) was applied for 1 h to prevent nonspecific
binding. Next, primary antibodies (1 μg/mL in TBS plus 0.05% Tween 20; TBST) were added
and incubated for 1 h for binding to the biomarker. TBST was used to rinse away unbound
antibodies for 15 min. Finally, the labeled secondary antibody (1 μg/mL in TBS) was incubated
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for 1 h, and the paper was washed again with TBST for 15 min. The dot blots were scanned via a
LI-COR ODYSSEY imaging system. The cross reactivity between each antibody and off-target
biomarker was also tested using the process above.
The attachment of each antibody to the GMA monolith was verified using fluorescence
images. To measure attachment to monoliths anti-CRF, anti-TNF, and anti-TAT were labeled at
a dye:antibody molar ratio of 10:1 and were filtered four times at 14,000 RPM for 15 min using a
10-kDa cutoff filter to remove excess dye. I directed a 532 nm laser through a 4X objective and
captured images with a Hamamatsu ORCA-Fusion CMOS camera (Bridgewater, NJ) using 10,
100, or 300 ms exposure times. First, a blank image of the monolith was taken before attaching
the antibody. Then, the monoclonal anti-CRF, anti-TNF, or anti-TAT labeled with Alexa Fluor
532 was immobilized onto the monolith overnight. Next, the monolith was rinsed with 20 mM
borate buffer pH 8 for 30 min and another monolith image was captured. Background-subtracted
fluorescence of the monolith with the labeled antibody and the control channel was determined
using Image J (imagej.nih.gov). To measure the background-subtracted fluorescence for
extracted PTB biomarkers, the same steps were used with monolith images taken at each stage of
the experimental process: loading, rinsing, and elution. Fluorescence values were normalized to
the signal after loading, and the average signal was determined from three replicates.
For the attachment of the multiple antibodies to the monolith, a mixture consisting of 4
µL each of anti-CRF, anti-TNF, and anti-TAT (1 mg/mL) was added to the device and allowed
to flow through the channel via capillary action. 20 mM borate buffer pH 8 was next added to the
reservoirs and the entire device was covered with parafilm and placed in a humid chamber
overnight to prevent the channel from drying. This reaction time allowed amine groups in the
antibody to bind covalently to the epoxy groups in the immunoaffinity monolith. Following
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overnight incubation, 0.1 M Tris buffer (pH 8.5) was flowed through the channel and then
incubated for 1 h to block any remaining epoxy groups. Finally, the channel was rinsed with 20
mM HEPES buffer pH 7 for 5 min. For control experiments, the monolith was blocked using
Tris buffer and no antibodies were incubated.
4.2.8 Immunoaffinity Extraction
The experimental set up was as follows: a 532 nm laser was used to induce fluorescence.
The fluorescence signal was recorded with a photomultiplier tube and digitized using LabVIEW
software. Experiments were then carried out in the following steps. First, channels were filled
with 20 mM HEPES buffer pH 7 and vacuum was applied for 1 min through the device as seen
in Figure 1E. Then, the vacuum was paused, the reservoir was emptied, the fluorescently labeled
analyte was loaded into the reservoir, and analyte was drawn through the channel by applying
vacuum for ~40 s. The labeled analyte was incubated in the monolith for 10 min, after which the
reservoir was washed three times with 20 mM HEPES buffer pH 7, and the monolith had 20 mM
HEPES buffer drawn through until the signal went back to baseline. Finally, the reservoir was
filled with 50 mM BCB and vacuum was applied for 1 min to elute the sample.
4.3 Results and Discussion
4.3.1 Antibody Characterization
Dot blots were used to confirm the compatibility between CRF, TNF, and TAT and their
respective antibodies, as well as their cross reactivity toward off-target antibodies. Figure 4.2
shows three replicate dot blots in each panel. Figure 4.2A displays a positive control for ferritin
and anti-ferritin binding. Figure 4.2B-D similarly shows binding between CRF and anti-CRF,
TNF and anti-TNF, and TAT and anti-TAT. Figure 4.2E shows that binding also occurs between
thrombin and anti-TAT. No binding was observed between antithrombin and anti-TAT as seen in
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Figure 4.2F. I hypothesize that rather than affinity interaction, thrombin nonspecifically sticks to
primary antibodies, and in Figure 4.2G, I confirmed that thrombin also binds non-specifically to
anti-ferritin. These dot blots demonstrate that the anti-CRF, anti-TNF, and anti-TAT antibodies
selected are appropriate for CRF, TNF, and TAT, and that thrombin by itself may stick
nonspecifically to antibodies.
I further studied the cross reactivity between CRF, TNF, and TAT, and off-target
antibodies, as shown in the dot blots in Figure 4.2H-M. No fluorescent dots were seen in any of
these experiments, which confirmed a lack of affinity binding between CRF, TNF, and TAT, and
off-target antibodies. These data further support the use of these anti-CRF, anti-TNF, and antiTAT antibodies for multiplex immunoaffinity experiments.

Figure 4.2 Dot blot assays on nitrocellulose membranes. Three duplicate dots of (A) positive control with
ferritin and anti-ferritin; (B) CRF and anti-CRF; (C) TNF and anti-TNF; (D) TAT and anti-TAT; (E)
thrombin and anti-TAT; (F) antithrombin and anti-TAT; (G) Thrombin and anti-ferritin. (H) CRF and
anti-TNF; (I) CRF and anti-TAT; (J) TAT and anti-TNF; (K) TAT and anti-CRF; (L) TNF and anti-TAT;
(M) TNF and anti-CRF.

4.3.2 SPR and BLI of PTB Biomarkers with their Target Monoclonal Antibodies
I obtained Kd data for CRF, TNF, and TAT with their monoclonal antibodies using either
SPR or BLI. Figure 4.3 shows the fitting curves for association and dissociation of CRF, TNF,
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and TAT with their corresponding antibodies. The Kd values for these three PTB biomarkers and
their monoclonal antibodies were calculated as seen in Table 4.1. The Kd values in Table 4.1
show that of these three, TAT has the strongest binding affinity toward its antibody, and CRF has
the lowest binding affinity toward anti-CRF. This means in a multiplex affinity column, CRF
will dissociate more readily from its target compared to TNF and TAT. The lower affinity for
CRF and anti-CRF likely is due to the smaller size of CRF, relative to TNF and TAT.

Table 4.1 Kd values for monoclonal anti-CRF, anti-TNF, and anti-TAT binding to their antigen.
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Figure 4.3 Association and dissociation data and fitting for CRF, TNF, and TAT binding to their
respective monoclonal antibodies. CRF and TNF data were collected from SPR. TAT data were obtained
with BLI. Different concentrations of (A) CRF, (B) TNF, or (C) anti-TAT.

4.3.3 Monolith Characterization and Modification
I used the same monolith formulation that Parker et al.12 developed to retain the PTB
biomarker, ferritin, using a single-antibody column. GMA monoliths were successfully formed
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inside channels as seen in Figure 4.1B. The morphology of a representative monolith was
determined using SEM as shown in Figure 4.1C-D. The SEM data in Figure 4.1C show that the
monolith is fully attached to the microfluidic channel wall. The monolith pores are randomly
distributed as seen in Figure 4.1D, and there is sufficient surface area for antibody
immobilization. I analyzed the pore and nodule sizes for my monoliths, which were 0.5 µm ± 0.1
μm (n=30) and 0.7 µm ± 0.1 μm (n=30), respectively.
I used fluorescence imaging to verify the attachment of antibodies to the affinity
monoliths, as seen in Figure 4.4. In the control monoliths in Figure 4.4A, C, and E the
fluorescence was much lower compared to the fluorescence observed when labeled anti-CRF,
anti-TNF, or anti-TAT was attached to the column in Figure 4.4B, D, and F. Figure 4.4G-I shows
the background-subtracted fluorescence on the monolith before and after antibody attachment;
fluorescence signal significantly increased for labeled anti-CRF, anti-TNF, and anti-TAT
columns compared to the control columns. This clear increase in fluorescence confirmed the
attachment of antibodies to PTB biomarkers on monoliths.
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Figure 4.4 Labeled antibody attachment to monoliths. Fluorescence images of (A, C, E) control
monoliths and fluorescently labeled monoclonal (B) anti-CRF, (D) anti-TNF, and (F) anti-TAT.
Background-subtracted fluorescence of monoliths before and after immobilization of labeled (G) antiCRF, (H) anti-TNF, and (I) anti-TAT. Error bars show the standard deviation for three replicates.

4.3.4 Immunoaffinity Extraction of PTB Biomarkers
I measured the fluorescence during elution after extraction of CRF, TNF, and TAT on
their respective, single-antibody-modified columns and control columns, from both buffer and
depleted human blood serum, as seen in Figure 4.5. During the elution step a peak appeared as an
increase in fluorescence signal at 5-10 s after flow started for each biomarker loaded from buffer
(Figure 4.5A-C). In contrast, little or no increase in the fluorescence signal occurred for the
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control monoliths lacking attached antibodies. The elution peaks appeared at similar times for the
three biomarkers, but they exhibited different shapes. In the depleted blood serum experiments
(Figure 4.5D-F), the elution peaks were seen at 5 s, 15 s, and 20 s for CRF, TNF, and TAT,
respectively. These peaks were generally wider and had higher signal compared to the peaks
observed for analyte loaded from buffer. These data demonstrate the ability to retain CRF, TNF,
and TAT individually on single-antibody columns after loading from either buffer or blood
serum.

Figure 4.5 Fluorescence during elution after extraction of labeled PTB biomarkers from their respective
single-antibody-modified columns (red) or a control monolith lacking attached antibody (blue) for (A, D)
100 nM CRF; (B, E) 30 nM TNF; and (C, F) 60 nM TAT in either (A-C) buffer or (D-F) depleted human
blood serum.
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Cross reactivity of each of the PTB biomarkers with off-target antibodies was tested as
shown in Figure 4.6 for fluorescence during elution from a column with the two off-target
antibodies for each biomarker, which was loaded from buffer. A small increase in the
fluorescence was seen for both the antibody and blocked column, which possibly resulted from
limited, nonspecific adsorption of each biomarker on the affinity column. These data clearly
confirm that there is little cross reactivity occurring between each biomarker and the other two
off-target antibodies.

Figure 4.6 Fluorescence during elution after extraction from buffer on an off-target multiplexed affinity
monolith (red) or a control monolith lacking attached antibodies (blue). Labeled (A) 100 nM CRF on antiTNF and anti-TAT; (B) 30 nM TNF on anti-CRF and anti-TAT; (C) 60 nM TAT on anti-CRF and antiTNF.
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I then tested extraction of individual PTB biomarkers spiked into human blood serum on
multiplexed antibody columns. As can be seen in Figure 4.7 small, narrow peaks were detected
between 5-10 s for the blocked monoliths, which likely resulted from limited adsorption of the
biomarker to the blocked column. However, a large peak in the fluorescence was observed at
5-10 s when each biomarker was eluted after extraction on a multiplexed antibody column. The
peak appearances were also similar to when they were run on a single-antibody column in Figure
4.5. These results show the ability to individually extract CRF, TNF, and TAT on multiplexed
antibody columns. I hypothesized that the most abundant proteins in serum might facilitate this
nonspecific interaction, so I used five-fold diluted serum that had been depleted of abundant
proteins in multiplexed studies.

Figure 4.7 Fluorescence during elution of a single PTB biomarker loaded from depleted human serum
and eluted from a multiplexed anti-CRF, anti-TNF, and anti-TAT monolith (red) or a control monolith
lacking attached antibodies (blue). (A) 100 nM CRF, (B) 30 nM TNF, and (C) 60 nM TAT.
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When I tested the individual protein biomarkers TNF and TAT, spiked into serum diluted
5-fold and loaded on blocked column, only a small elution peak was observed as seen in Figure
4.8A-B. This indicates that similar to the result in Figure 4.7B-C neither TNF nor TAT interacted
significantly with the blocked column, even in the serum matrix that had not been depleted of
abundant proteins. In contrast, a much larger elution peak was observed when both TNF and
TAT were spiked into diluted blood serum and loaded on a blocked column as seen in Figure
4.8C. This result indicates some sort of combined interaction between TNF and TAT and
components in blood serum, even on a blocked column. I hypothesized that the most abundant
proteins in serum might facilitate this nonspecific interaction, so I used five-fold diluted serum
that had been depleted of abundant proteins for multiplexing experiments.
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Figure 4.8 Fluorescence during elution after extraction of labeled (A) 30 nM TNF, (B) 60 nM TAT and
(C) TNF (30 nM) and TAT (60 nM) from five-fold diluted human blood serum using a control monolith
lacking attached antibodies (blue).

I studied the retention and elution from a combined anti-CRF, anti-TNF, and anti-TAT
monolith by running a mixture of CRF, TNF, and nM TAT on either a multiplexed antibody
column or a blocked column. Figure 4.9A shows an increase in the fluorescence signal during
elution of all three biomarkers loaded from buffer on a combined anti-CRF, anti-TNF, and antiTAT column as compared to a blocked column. The elution peak appeared at 7 s and was taller
and wider than the peak from the blocked column. These data indicate successful retention and
elution of these three PTB biomarkers in buffer using a multiplexed antibody column.
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A similar experiment was performed wherein the biomarkers were spiked into depleted
blood serum and loaded, and then eluted as seen in Figure 4.9B. An elution peak was observed
initially at 5 s with a second, broader peak starting at 10 s. In contrast, a much smaller peak
appeared at 5 s and the signal quickly went back to the baseline in the control experiment. This
contrast with the large peak seen in Figure 4.8C supports the idea that the abundant serum
proteins were responsible for the nonspecific binding observed in multiplexing experiments in
serum when those proteins had not been removed. These results confirm successful retention and
elution of these PTB biomarkers from a multiplexed monolith compared to a column lacking
antibodies in a 3D printed device. These results also show promise for future extension to
working with all nine PTB biomarkers on a single multiplexed antibody column.

Figure 4.9 Fluorescence during elution after extraction on a combined anti-CRF, anti-TNF, and anti-TAT
monolith (red) or a control monolith lacking attached antibodies (blue) for a mixture of labeled 100 nM
CRF, 30 nM TNF, and 60 nM TAT from (A) buffer and (B) depleted human blood serum.
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Further confirmation of the selective retention and elution of PTB biomarkers on a
multiplexed immunoaffinity monolith is found in Figure 4.10. I took fluorescence images of a
monolith after loading, rinsing, and elution of these three PTB biomarkers in depleted human
blood serum on multiplexed immunoaffinity columns. The background-subtracted fluorescence
seen in Figure 4.10 demonstrates that after the biomarker mixture was first loaded into a column,
the fluorescence signal was at its highest. The control columns showed a drop in signal after
rinsing to remove any nonspecifically bound analyte, indicating that the biomarkers were not
strongly retained on blocked columns. However, the fluorescence signal was considerably higher
after the rinsing step for antibody columns, showing specific retention of the biomarkers on
multiplexed affinity monoliths compared to control columns. The signal on the monolith dropped
more than twofold (with a p value of 0.14) after elution from the antibody columns, indicating
some removal of retained PTB biomarkers. Elution from the control columns led to a small
decrease in the already near background signal (with a p value of 0.28). In this initial evaluation
the p values for the difference in signal after elution are not statistically significant, either for the
control or antibody experiment. These data show limited biomarker retention for the control
columns, with considerably more retention and elution of the biomarkers on the antibody
columns, further supporting the use of these multiplexed immunoaffinity columns for PTB
biomarker sample preparation.
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Figure 4.10 Normalized fluorescence signal on a monolith during the extraction of a mixture of 300 nM
CRF, 90 nM TNF, and 180 nM TAT spiked into depleted human blood serum. (Blue) control monolith
without attached antibodies; (red) monolith with attached antibodies. Error bars show the standard
deviation for four replicates. No error bars are given for the loading data because they were normalized to
1.

I was able to extract CRF spiked into human blood serum with an antibody having
moderate affinity (see Table 4.1). However, extraction of native CRF from human blood serum
may require an antibody with higher affinity binding compared to the current one. In contrast,
TAT has high affinity toward anti-TAT, and with a PTB risk level of ~5 µM,8 I should readily be
able to extract TAT from blood serum at clinical levels.
4.4 Conclusion
To improve sample preparation for analysis of biomarkers for maternal and fetal
wellness, I created 3D printed microfluidic devices with multiplexed immunoaffinity monoliths.
I characterized antibodies to target three PTB biomarkers. I also verified attachment of these
antibodies to immunoaffinity columns using fluorescent imaging. Furthermore, I demonstrated
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successful retention and elution of individual PTB biomarkers on single-antibody columns from
both buffer and depleted human blood serum. Minimal cross reactivity was observed between
each biomarker and the two off-target antibodies. Each of the three individual biomarkers were
successfully extracted from multiplexed antibody columns. Finally, I demonstrated selective
retention and elution of three PTB biomarkers on a multiplexed immunoaffinity column. In the
future, I plan to multiplex additional antibodies on these columns, which should allow extraction
of the whole panel of nine PTB biomarkers using a single immunoaffinity column. Additionally,
these immunoaffinity monoliths form a significant part of a potential integrated chip that could
be used in point-of-care in early identification of the risk of preterm birth.
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5. CONCLUSIONS AND FUTURE WORK
5.1 Conclusions
The focus of this dissertation is to develop immunoaffinity extraction methods for
preterm birth biomarkers in human blood serum using 3D printed microfluidic devices. I was
able to develop immunoaffinity columns for six of the nine PTB biomarkers, laying the
foundation to simultaneously extract multiple PTB biomarkers in these systems. My work forms
part of a larger effort to rapidly analyze the panel of nine PTB biomarkers with low cost to
provide a way for doctors to predict risk for early labor.
5.1.1 Immunoaffinity Monoliths for PTB Peptide Extraction from Blood Serum
I developed immunoaffinity monoliths in 3D printed microfluidic devices, building on
one developed by Parker et al.,1 and designed to extract and elute a PTB peptide, corticotropin
releasing factor, from spiked blood serum as described in chapter 2. This was the first
demonstration of an immunoaffinity column in a 3D-printed device for the extraction of a
peptide biomarker.
5.1.2 Antibody Characterization and Immunoaffinity Extraction of PTB Biomarkers
To support of my goal to develop immunoaffinity extraction of PTB biomarkers in 3D
printed microfluidic devices, I characterized polyclonal and monoclonal antibodies toward PTB
biomarkers in chapter 3. This characterization is necessary to identify appropriate antibodies for
all nine PTB biomarkers for future retention and elution of mixtures of PTB biomarkers on
immunoaffinity columns. Affinity binding between antigen and antibody was also studied to
determine the strength of the binding between each biomarker toward its antibody, in support of
subsequent multiplex experiments. I used polyclonal antibodies to target peptide 2, peptide 3, and
lactoferrin. When I combined lactoferrin, ferritin1 and CRF, I found that the polyclonal antibodies
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were not specific to just the target biomarkers, and this off-target binding made polyclonal
antibodies a less desirable option for future experiments. To overcome the cross reactivity issue
with polyclonal antibodies, I evaluated monoclonal antibodies and was able to significantly reduce
off-target binding between PTB protein biomarkers and non-target antibodies. Using monoclonal
antibodies, I was able to demonstrate the immunoaffinity extraction of three PTB biomarkers:
ferritin and lactoferrin from buffer, and peptide 2 from both buffer and blood serum.
5.1.3 Immunoaffinity Extraction of Multiplexed PTB Biomarkers
I optimized experimental conditions and obtained successful multiplexed retention and
elution of three PTB biomarkers from both buffer and depleted human blood serum as described
in chapter 4. An immunoaffinity monolith was formed inside 3D printed microfluidic devices via
UV polymerization. Attachment of antibodies to the monolith and the absence of cross reactivity
between PTB biomarkers and non-target antibodies were demonstrated. Equilibrium dissociation
constant values for three PTB biomarkers toward their monoclonal antibodies were determined. A
mixture of three monoclonal antibodies was immobilized on a monolith to enrich corticotropin
releasing factor, tumor necrosis factor-α receptor type 1, and thrombin-antithrombin. Fluorescence
on the column was measured to observe successful retention and elution of the three PTB
biomarkers. This work shows important progress toward developing monoliths that can selectively
extract all nine PTB biomarkers from human blood serum as a part of a complete diagnostic
system.
5.2 FUTURE WORK
Antibody characterization was done for seven of the nine PTB biomarkers, but remains to
be completed for peptide 1 and defensins. Defensins constitute a group of peptides, and at present
it is not known which defensins are correlated to PTB risk. Future work on mass spectrometry
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could determine which defensins should be included in the PTB biomarker panel. Although the
dissociation constants for three PTB biomarkers were reported in this dissertation, the Kd values
for the remaining six monoclonal antibodies need to be determined. A lack of nonspecific binding
was observed between five PTB biomarkers and off-target monoclonal antibodies, but the
interaction between the remaining PTB biomarkers toward off-target antibodies needs to be
determined for eventual successful extraction of all nine PTB biomarkers. Additionally, an offchip sample preparation step was done to separate PTB biomarkers from abundant proteins in
serum. Finally, immunoaffinity extraction has been shown for four PTB biomarkers in blood
serum; however, extraction of the remaining five PTB biomarkers from blood serum needs to be
demonstrated. The development of an immunoaffinity column to combine the entire panel of the
PTB biomarkers may need optimization of conditions including buffer pH, ionic strength, salt
additive, and composition.
As described in this dissertation, I achieved successful retention and elution of many PTB
biomarkers in immunoaffinity columns; however, I did all experimental steps of loading, rinsing,
and elution manually. Collaborators in Dr. Nordin’s lab have shown that pumps and valves can be
3D printed in microfluidic devices;2-3 adding these components to my design could improve
devices by allowing automatic extraction of PTB biomarkers. Adding pumps and valves to the
design will also facilitate transferring analyte from the immunoaffinity column to other 3D printed
analysis components.
The fabrication process could be improved by creating a 3D printed cover to place in the
reservoir to prevent liquid from evaporating during the overnight incubation step and keep the
channel wet to prevent bubbles from forming inside the channel. Multiple monoliths could be
added to the current design to purify the PTB biomarkers in multiple groups based on different
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extraction conditions. I could also add multiple inlet channels to the current design, controlled by
valves for solvent switching, to allow consistent flow and automated extraction of multiple PTB
biomarkers.
The long term goal of this work is to create 3D printed microfluidic devices containing three
modules: immunoaffinity extraction, solid phase extraction and fluorescent labeling, and
electrophoresis separation. In this dissertation I focused on the immunoaffinity extraction portion
and demonstrated the extraction of multiple biomarkers from human blood serum using an
immunoaffinity column. Next, it is necessary to integrate the immunoaffinity module with on-chip
labeling and then with downstream separation. This will allow researchers to rapidly quantify the
entire panel of PTB biomarkers from human blood serum as a part of a PTB risk analysis system.
This work shows progress toward the long-term goal of assessing PTB and preventing early labor
by development of immunoaffinity extraction of multiple PTB biomarkers from human blood
serum. The 3D printed microfluidic devices used in this work are ideal for extraction of PTB
biomarkers, and also show potential for use in detection of biomarkers for other diseases such as
cancer.
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